Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti- CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) …

Sep 14, 2018 · Lumoxiti (moxetumomab pasudotox, formerly CAT8015 or HA22) is a CD22-directed cytotoxin and a first-in-class treatment in the US for adult patients with relapsed or …

Lumoxiti (moxetumomab pasudotox) is used to treat hairy cell leukemia. Includes Lumoxiti side effects, interactions and indications.

Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell …

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy …

Sep 3, 2020 · LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including …

On Sept. 13, 2018, the Food and Drug Administration approved moxetumomab pasudotox-tdfk (LUMOXITI, AstraZeneca Pharmaceuticals LP), a CD22-directed cytotoxin indicated for adult …

Jan 29, 2025 · The recommended dose of LUMOXITI is 0.04 mg/kg administered as a 30-minute intravenous infusion on Days 1, 3, and 5 of each 28-day cycle. Continue LUMOXITI treatment …

Find patient medical information for Lumoxiti intravenous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

What is Lumoxiti and what is it used for? Lumoxiti is a cancer medicine used to treat adults with hairy cell leukaemia, blood cells where too many B cells (a type of white blood cell) are …